Hiromichi Maeda, Koji Oba, Kosuke Kashiwabara, Toru Aoyama, Shuhei Mayanagi, Mitsuro Kanda, Michitaka Honda, Masaru Muto, Junichi Sakamoto, Hisakazu Yamagishi, et al. Efficacy of Adjuvant Chemotherapy for T1-2 Stage III Colorectal Cancer. Cancers. 2025
Chikako Iwai, Taisuke Jo, Akira Okada, Asahi Fujita, Takaaki Konishi, Koji Oba, Yohei Hashimoto, Hideo Yasunaga. Association between immune checkpoint inhibitors and uveitis in patients with lung cancer, renal cell carcinoma, or malignant melanoma. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2025
Shigenobu Emoto, Kazushige Kawai, Koji Oba, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Yuichiro Yokoyama, Shinya Abe, Kensuke Kaneko, Yuzo Nagai, et al. Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer. International journal of colorectal disease. 2025. 40. 1. 76-76
Hirohiko Motoki, Izuru Masuda, Koji Oba, Shinji Yasuno, Yoshito Inobe, Nobuyuki Azuma, Masako Waki, Takeshi Kimura, Wataru Shoin, Koji Yoshie, et al. Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes - Results From the EMPYREAN Study. Circulation journal : official journal of the Japanese Circulation Society. 2025
Akiko Sankoda, Yugo Nagae, Kayo Waki, Wei Thing Sze, Koji Oba, Makiko Mieno, Masaomi Nangaku, Toshimasa Yamauchi, Kazuhiko Ohe. Correction: Glycemic Control, Renal Progression, and Use of Telemedicine Phone Consultations Among Japanese Patients With Type 2 Diabetes Mellitus During the COVID-19 Pandemic: Retrospective Cohort Study. JMIR diabetes. 2025. 10. e72076
Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).
(JOURNAL OF CLINICAL ONCOLOGY 2019)
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
(ARTHRITIS & RHEUMATOLOGY 2018)
SAPPHIRE: A randomized phase II study of mFOLFOX6+panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6+panitumumab in patients with colorectal cancer.
(JOURNAL OF CLINICAL ONCOLOGY 2018)
Trial in progress: A phase II study of second-line FOLFIRI plus panitumumab after first-line FOLFOX plus panitumumab for RAS wild-type colorectal cancer with evaluation of circulating tumor DNA.
(JOURNAL OF CLINICAL ONCOLOGY 2018)
Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients' data from three large phase III randomized trials
(ANNALS OF ONCOLOGY 2017)